TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer Available to Purchase

Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such as PD-L1/PD-1 or CTLA4 blockade, are ineffective for the treatment of ovarian cancer. In this study, we demonstrate that for ovarian cancer, Toll-like receptor 5 (TLR5) signaling, for which the only known ligand is bacterial flagellin, governed failure of PD-L1 and CTLA4 blockade. Mechanistically, chronic TLR5 signaling on CD11c⁺ cells in vivo and in vitro impaired the differentiation of functional IL-12–producing XCR1⁺CD103⁺ conventional type 1 dendritic cells, biasing CD11c⁺ precursor cells toward myeloid subsets expressing high levels of PD-L1. This culminated in impaired activation of CD8⁺ T cells, reducing CD8⁺ T-cell function and ability to persist within the ovarian tumor microenvironment. Expansion of XCR1⁺CD103⁺ conventional type 1 dendritic cells in situ using Flt3L-Ig in combination with PD-L1 blockade achieved significant survival benefit in TLR5 knockout mice bearing ovarian tumors, whereas no benefit was observed in the presence of TLR5 signaling. Thus, we have identified a host-intrinsic mechanism leading to the failure of PD-L1 blockade for ovarian cancer, demonstrating that chronic TLR5 signaling on CD11c⁺ cells is a barrier limiting the efficacy of checkpoint therapy.